NEW YORK (360Dx) – The Federal Trade Commission said today that Becton Dickinson and CR Bard have agreed to divest two medical device product lines to settle its complaint that the proposed $24-billion acquisition would negatively impact competition.

Under the settlement, BD will divest its soft tissue core-needle biopsy product line and CR Bard will divest its Aspira product line of tunneled home drainage catheters and accessories.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.